Robert Baiocchi, MD, Hematology, Columbus, OH, James Cancer Hospital and Solove Research Institute

RobertAlanBaiocchiMDPhD

Hematology Columbus, OH

Hematologic Oncology

Professor, Internal Medicine, Ohio State University College of Medicine

Dr. Baiocchi is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Baiocchi's full profile

Already have an account?

Education & Training

  • Ohio State University Hospital
    Ohio State University HospitalFellowship, Hematology/Oncology, 2001 - 2004
  • Ohio State University Hospital
    Ohio State University HospitalResidency, Internal Medicine, 1999 - 2001
  • The Ohio State University College of Medicine
    The Ohio State University College of MedicineClass of 1999
  • SUNY BUffaloMD, medicine, 1995 - 1997
  • State University of New York CollegePh.D, Physiology, 1994
  • State University of New York CollegeM.S., Natural Science, 1993
  • State University of New York CollegeB.S., Biology, 1989

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2000 - 2021

Awards, Honors, & Recognition

  • Early Career Innovator of the Year Nomination The Ohio State University, 2012
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
  • Innovation Award-Semi Finalist Inventor of the Year Nomination Tech Columbus, 2011
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • A Phase I study of Vorinostat maintenance after autologous transplant in high risk lymphoma  
    Hofmeister CC, Williams N, Geyer S, Hade EM, Bowers MA, Earl CT, Vaughn J, Bingman A, Humphries K, Lozanski G, Baiocchi RA, Jaglowski SM, Blum K, Porcu P, Flynn J, Pen..., Leuk Lymphoma, 1/1/2015
  • The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and ref...  
    Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM Jr, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA, Br J Haematol, 1/1/2015
  • AIDS Malignancy Consortium AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma  
    Noy A, Lee JY, Cesarman E, Ambinder R, Baiocchi R, Reid E, Ratner L, Wagner-Johnston N, Kaplan L, Blood, 1/1/2015
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatm...
    Robert A Baiocchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of...
    Robert A Baiocchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • PRMT5 Is a Key Epigenetic Regulator That Promotes Transcriptional Activation in Mantle Cell Lymphoma By Regulating the Lysine Methyltransferase SETD7 and MLL1 Activity
    Robert A Baiocchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • PRMT5 Is Upregulated in Activated T Cells and Is a Novel Therapeutic Target for Acute Gvhd 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Post graduate career options for the physician scientist 
    Chicago, IL - 1/26/2015
  • Targeting Histone Methyltransferases and Demethylases track 
    Boston, MA - 1/24/2015
  • Join now to see all

Other

  • It’s All About Health 
    Baiocchi RA, Show Joy 106.3
    1/5/2011
  • OSU James Care East Expansion 
    Baiocchi RA, Show Joy 106.3
    1/5/2011

Press Mentions

  • OSU Doctor Looks into Viruses That May Lead to Cancer
    OSU Doctor Looks into Viruses That May Lead to CancerMay 11, 2019 22:54
  • Atara Biotherapeutics Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results from a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus (EBV)-Associated Cancers
    Atara Biotherapeutics Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results from a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus (EBV)-Associated CancersNovember 09, 2017 14:57
  • Possible New Target for Future Brain Cancer Drugs
    Possible New Target for Future Brain Cancer DrugsFebruary 12, 2016 05:02

Grant Support

  • Development Of Novel Compounds To Inhibit PRMT5 Enzyme In High Grade AstrocytomasNational Institute Of Neurological Disorders And Stroke2010–2011
  • Development Of Vaccine Strategies To Prevent EBV+ Lymphoma In Patients With HIVNational Cancer Institute2009–2010
  • Ptld: Cytokine Production And Gene PolymorphismsNational Cancer Institute2005
  • Biologic Modifier Therapies In AIDS MalignanciesNational Cancer Institute2003

Hospital Affiliations